Century Therapeutics (IPSC) EBITDA (2020 - 2026)
Century Therapeutics (IPSC) posted quarterly EBITDA of -$23.7 million for Q1 2026, down 131.93% year-over-year from $74.2 million in Q1 2025, and down 14.69% quarter-over-quarter from -$20.7 million in Q4 2025.
Century Therapeutics (IPSC) EBITDA (2020 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has reported EBITDA for 7 consecutive years, with -$23.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 131.93% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at -$115.1 million (down 252.58% YoY), while the FY2025 annual figure was -$17.3 million, up 87.5% from the prior year.
- EBITDA retreated to -$23.7 million in Q1 2026 per IPSC's latest filing, from -$20.7 million in the prior quarter.
- Across five years, EBITDA topped out at $74.2 million in Q1 2025 and bottomed at -$43.8 million in Q4 2023.
- Historically, EBITDA has averaged -$27.0 million across 5 years, with a median of -$34.7 million in 2025.
- Annual changes were most pronounced in 2025 — EBITDA soared 336.92% — and 2026, when it sank 131.93%.
- Century Therapeutics' EBITDA stood at -$33.3 million in 2022, then sank by 31.39% to -$43.8 million in 2023, then advanced by 14.8% to -$37.3 million in 2024, then jumped by 44.61% to -$20.7 million in 2025, then fell by 14.69% to -$23.7 million in 2026.
- Business Quant data shows IPSC's EBITDA at -$23.7 million in Q1 2026, -$20.7 million in Q4 2025, and -$36.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | -36.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.53 Mn |
| Mar 31, 2026 | -23.68 Mn |
| Dec 31, 2025 | -20.65 Mn |
| Sep 30, 2025 | -36.12 Mn |
| Jun 30, 2025 | -34.66 Mn |
| Mar 31, 2025 | 74.18 Mn |
| Dec 31, 2024 | -37.28 Mn |
| Sep 30, 2024 | -34.79 Mn |
| Jun 30, 2024 | -34.76 Mn |
| Mar 31, 2024 | -31.31 Mn |
| Dec 31, 2023 | -43.76 Mn |
| Sep 30, 2023 | -35.63 Mn |
| Jun 30, 2023 | -35.08 Mn |
| Mar 31, 2023 | -32.08 Mn |
| Dec 31, 2022 | -33.31 Mn |
| Sep 30, 2022 | -31.74 Mn |
| Jun 30, 2022 | -31.35 Mn |
| Mar 31, 2022 | -37.44 Mn |
| Dec 31, 2021 | -27.97 Mn |
| Sep 30, 2021 | -25.83 Mn |